Want to see TSE:VM full AI Analyst Report?
VM Stock Chart & Stats
C$0.17
>-C$0.01(-5.56%)
At close: 4:00 PM EST
C$0.17
>-C$0.01(-5.56%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.20
Previous CloseN/A
Volume12.11K
Average Volume (3M)72.03K
Market Cap
C$29.42M
Enterprise ValueC$14.81
Total Cash (Recent Filing)C$441.87K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding226,342,350
10 Day Avg. Volume61,621
30 Day Avg. Volume72,034
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low reported debt (≈$40k; debt-to-equity ~0.06) provides structural financial flexibility. With limited leverage the company can withstand ongoing operating losses longer, access additional capital on more favorable terms, and avoid near-term solvency pressure while pursuing qualification and commercialization steps.
Improving Revenue TrendA 52.6% TTM revenue increase to $47.2k demonstrates early commercial traction from a minimal base. If sustained, this trend supports scaling of processing and higher-value pharmaceutical product sales. Durable growth in top-line activity is a necessary precursor to margin expansion and longer-term viability.
Niche, Higher-Value Product FocusThe company's strategic focus on pharmaceutical-grade barium sulfate for diagnostic imaging targets a regulated, higher-margin niche versus commodity barite. Value-added processing and qualification pathways create potential durable competitive advantage and licensing or supply partnerships if product specs and regulatory clearances progress.
Bears Say
Deep Negative ProfitabilityPersistently negative gross profit and large net losses signal the cost base far exceeds revenue. Such structural unprofitability indicates the business is pre-scale and must materially expand sales or materially cut costs to achieve sustainable margins, a multi-quarter challenge given current scale.
Cash Burn / Weak Cash GenerationOperating and free cash flow both at -$1.01M TTM show losses convert into real cash outflows. Ongoing negative cash generation reduces runway, forces reliance on external financing, and can delay product qualification or commercialization initiatives if additional capital is unavailable or costly.
Shareholder Equity ErosionA sharp decline in shareholders' equity from $1.25M to ~$0.41M reflects cumulative losses and weak returns. This erosion reduces the company's balance-sheet buffer, increases vulnerability to operational setbacks, and raises the likelihood of dilutive capital raises to fund growth or maintain operations.
Voyageur Pharmaceuticals News
VM FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was C$0.07 and its highest was C$0.20 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is C$29.42M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Nov 02, 2026 which is in 90 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Voyageur Pharmaceuticals released its earnings results on Jul 24, 2026. The company reported -C$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 226,342,350 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Voyageur Pharmaceuticals reported an EPS of -C$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:VM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine. It possesses complete ownership of three barium sulfate deposits in British Columbia, Canada, two of which are of a quality appropriate for the pharmaceutical barite sector. Furthermore, Voyageur holds stakes in a valuable brine project in Utah, United States, known for its high concentrations of iodine, lithium, and bromine. The company transitioned from its previous name, Voyageur Minerals Ltd., to Voyageur Pharmaceuticals Ltd. in December 2019. Its corporate headquarters are located in Calgary, Canada.